NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Verastem, Inc. VSTM
15 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$30.9M
▲ 209.1% vs FY2024
EPS · FY25
$-3.02
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-1480.2%
Net margin · FY25
-677.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 30.9M
Revenue, FY2025 · full 15-year series below
Revenue
Net income
The company lost 678 cents on every revenue dollar this year.
Per share
USD -3.02
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-1480.2%
Return on equity, FY2025
ROE
Operating margin-550.3%
Net margin-677.6%
Return on assets-120.4%
Each USD of equity lost 1480 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−19.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+128.4%
−19.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.08B
Shares outstanding, FY2025
Change, 5 years+193.9%
Change, 10 years—
The share count grew 194% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 246.4M
total assets, end of FY2025
Total assetsUSD 246.4M
EquityUSD 57.2M
CashUSD 205.0M
Current ratio3.09×
Equity funds 23% of total assets.
History
15 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Revenue $B
0.0
0.0
·
0.0
0.0
0.1
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
·
0.0
·
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Net income $B
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−3.02
−3.66
−3.96
−4.57
−4.90
−0.44
−2.00
−1.37
−1.76
−0.99
−1.61
−2.07
−1.82
−1.70
−10.59
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−1480.2
−917.4
−166.8
−109.4
−70.2
−110.6
−227.0
−79.6
−104.3
−41.7
−60.5
−51.8
−39.6
−82.3
·
Shares out B
0.08
0.04
0.03
0.02
0.19
0.17
0.08
0.07
0.05
0.04
0.04
0.03
0.03
0.02
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
45 of 45
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed